Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBER0Q)

• Drug Name: Hu5F9-G4 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Myelodysplastic syndrome	2A37	Phase 3	[1]
B-cell non-hodgkin lymphoma	2B33.5	Phase 1/2	[2]
Colorectal cancer	2B91.Z	Phase 1/2	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
Acute myeloid leukaemia	2A60	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DMBER0Q

Molecule-Related Drug Atlas

Drug(s) Targeting Leukocyte surface antigen CD47 (CD47)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Evorpacept	DMJTX7Q	Gastric cancer	2B72	Phase 2/3	[4]
PF-07901801	DMEVYHR	Diffuse large B-cell lymphoma	2A81	Phase 2	[5]
ALX148	DMGQX0U	Myelodysplastic syndrome	2A37	Phase 1/2	[2]
DSP-107	DM8K0PR	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
AO-176	DMXU98C	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
TG-1801	DM3K4FY	B-cell lymphoma	2A86	Phase 1	[8]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[9]
TTI-621	DMDNPAV	Haematological malignancy	2B33.Y	Phase 1	[10]
TTI-622	DMOCQ4K	Lymphoma	2A80-2A86	Phase 1	[11]
IBI188	DMXUJ1P	Myelodysplastic syndrome	2A37	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen CD47 (CD47)	TT28S46	CD47_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04313881) Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-1751.
• [5] ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of KAHR Medical.
• [7] Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
• [8] Clinical pipeline report, company report or official report of TG Theraputics.
• [9] Clinical pipeline report, company report or official report of Shattuck Labs.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Clinical pipeline report, company report or official report of Trillium Therapeutics.
• [12] Clinical pipeline report, company report or official report of Innovent Biologics.